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Starting from the easily accessible 24-O-tert-butyldimethylsilyl-22(R)-dihydro-28-oxoascomy-
cin, methodologies that allow replacement of the cyclohexylvinylidene moiety of ascomycin
by various other substituents are described. In addition, a so far unknown reactivity of the
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INTRODUCTION
The 23-membered macrolactam ascomycin (1, Scheme 1),
a fermentation product originally isolated from Strepto-
myces hygroscopicus var. ascomyceticus2 for its antifu-
gal activity, has later been shown to be a structurally clo-
sely related congener of the potent immunomodulator FK
506 (tacrolimus, 2).3 Pimecrolimus (Elidel®, SDZ ASM
981, 3) derived from ascomycin and featuring a more
lipophilic C-28 side chain has been shown to possess a
high therapeutic potential for the treatment of inflamma-
tory skin diseases. Pimecrolimus cream (1 %), which
combines a skin selective, anti-inflammatory activity with
a low risk of systemic side effects, has recently been
launched on the market for the treatment of atopic der-
matitis.4 As depicted in Scheme 1, macrolactams consist
of two functional molecular domains:5 a binding domain
(left part of the molecule) responsible for binding to the
intracellular cytosolic receptor (macrophilin) and an ef-
fector domain (right part of the molecule) interacting
with the target enzyme. Consequently, only minor struc-
tural changes are tolerated within these domains without
provoking a considerable loss of biological activities.3a
The role of the cyclohexyl part is, however, not comple-
tely clear,6 although there have been numerous reports de-
scribing modification of this part of the structure in FK
506 and its 21-ethyl analogue ascomycin.7
Previously, we reported a practical and versatile
method for chemoselective removal of the cyclohexyl
residue of precursor 4 leading to C-28-ketone 5.8 The
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procedure is accomplished in four steps (Scheme 2).
Starting from the 24,33-O-bis-silylated ascomycin deriv-
ative 4, the synthesis of intermediate 5 involves protec-
tion of the C-19/C-20 double bond through reduction of
the C-22-carbonyl group with K-selectride®, followed
by 5-endo-cyclization of the resulting C-22-alcohol with
the C-19/C-20 double bond using an oxymercuration re-
action, ozonolysis of the exocyclic C-28/C-29 double
bond and finally regeneration of the C-19/C-20 double
bond by treatment with an acid. This paper provides the
synthetic basis for replacements of the cyclohexyl-pro-
penyl side chain.
RESULTS AND DISCUSSION
Having the versatile 28-oxo-ascomycin derivative 5 in
our hands, we first directed the addition of several hy-
droxylamine- and hydrazine nucleophiles to C-28 carbo-
nyl group of 5 (Scheme 3). Thus, treatment of 5 with an
18 R. ZIMMER et al.























Ascomycin (1): R21 = Et; R33 =
FK 506 (2): R21 = Allyl; R33 =
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7 X = OBn ( : = 81:19)Z E
5
(R = TBDMS)
9 X = OCH CH OH ( : 75:25)2 2 Z E =
6 X = OH (60:40)
reaction conditions
Reaction conditions. For : NH OH · HCl, EtOH, r.t., 24 h, yield: 59 %; for : BnONH , PPTS, benzene, r.t.,
5 d, yield: 83 %; for : H NOCH CH OH ( ), PPTS, benzene, r.t., 6 d, yield: 88 %; for : H NCONHNH · HCl,
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11 X = NHTos (single isomer)
10 X = NHCONH (94:6)2
Scheme 3.
excess of hydroxylamine hydrochloride in ethanol at room
temperature provided the expected oxime 6 in 59 % yield
as a mixture of two geometrical isomers (60 : 40). In the
presence of catalytic amounts of pyridinium p-toluene-
sulfonate (PPTS), O-benzyl hydroxylamine converted ke-
tone 5 into oxime ether 7 in a good yield (83 %) and with
remarkable Z-selectivity (Z-7 : E-7 = 81:19). Analogously,
the reaction of 5 with O-(2-hydroxyethyl)-hydroxylamine
(8)9 provided oxime ether 9 as a mixture of geometrical
isomers in excellent yield (88 %; Z-9 : E-9 = 75 : 25). It is
noteworthy that the Z/E ratios were deduced from the ob-
served chemical shifts of the C=NR adjacent positions10
and from NOESY experiments.
Similar results were obtained with semicarbazide hy-
drochloride and tosylhydrazine (Scheme 3). Thus, treat-
ment of compound 5 with semicarbazide hydrochloride
in the presence of sodium acetate at 70 °C afforded se-
micarbazone 10 in 51 % yield as a mixture of two iso-
mers in a 94 : 6 ratio. Preparation of tosylhydrazone 11
was achieved under standard reaction conditions, as de-
scribed by Donaldson and Iida,11 with tosylhydrazine in
acetic acid. Notably, tosylhydrazone 11 was obtained as
a single isomer. Gratifyingly, upon treatment of 5 with
N-nucleophiles, no products reflecting C=N bond forma-
tion at C-9 could be detected as by-products, though such
transformations are reported in the literature.12
Having accomplished the addition of N-nucleophiles
on the C-28 carbonyl group of 5, we explored the reac-
tivity of 5 towards some C-nucleophiles (Scheme 4). Re-
action with one of the simplest C-nucleophiles, i.e., cyano-
trimethylsilane in the presence of catalytic amounts of
boron trifluoride etherate, converted 5 into an insepara-
ble mixture of two diastereoisomeric cyanohydrines 12,
albeit in a low yield (36 %, ratio of the isomers 60 : 40).
The low yield is not so surprising since it is known from
the literature that the masked tricarbonyl moiety of asco-
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mycin is highly sensitive towards cyanide.13 Similarly to
the formation of 12, the aldol type reaction of 5 with O-
(tert-butyldimethylsilyl) ketene acetal 13 / BF3  OEt214,15
yielded the expected -hydroxy ester 14 (48 %; 14a : 14b
= 70 : 30). In contrast, employing silyl enol ethers as nu-
cleophilic components, the expected Mukaiyama reaction
failed; only the starting material could be recovered. Ef-
forts to add organolithium reagents at the C-28 position
of 5 gave only poor results. Although treatment of 5 with
methyllithium allowed isolation of the desired tertiary al-
cohol 15 in a low yield (20 %), no product was observed
with phenyllithium and lithiated methoxyallene.16 How-
ever, we had to learn that basic reaction conditions ag-
gravate the regioselective addition of C-nucleophiles.
Attempts to establish a carbon-carbon double bond
at C-28 of compound 5 via a Wittig or Wittig-Horner
olefination reaction were unsuccessful. A variety of re-
action conditions and various Wittig (or Wittig-Horner)
reagents were examined, but almost no reaction took place
and only the starting material could be recovered. Sur-
prisingly, when the reaction of 5 was carried out with a
large excess of stabilized Wittig reagent 16 under more
forceful reaction conditions (65 °C, 10 d), we observed
an unexpected reaction leading to the furano derivatives
17 (11 % yield) and 18 (4 % yield) (Scheme 5). Structure
elucidations of 17 and 18 are based on 1H and 13C NMR
spectra and are supplemented by NOE, HMBC and HSQC
experiments. The resulting compound 18 possesses a fu-
ran moiety that incorporates the C-9 and C-10 atoms of
the macrolide. A 3JCH C-40–O–C-22 long-range cou-
pling in compound 18 confirms that the furan unit and
the C-22 atom are connected on the same oxygen atom.
Inspection of the carbon skeleton of 17 clearly re-
veals that two equivalents of the Wittig reagent 16 have
been incorporated. A possible explanation for the forma-
tion of the surprising compound 17 is outlined in Scheme
6 and assumes that first a common Wittig reaction at C-9
carbonyl group in 5 gives the hemiketal A, which has
the property of being in equilibrium with its ring opened
structure B. Alternatively, liberation of the C-10 carbonyl
group might occur first, followed by the olefination step
to give the same intermediate B and 1,4-addition of a se-
cond equivalent of ylide 16 at the newly formed activat-
ed double bond of B in a Michael-type reaction17 might
produce the highly functionalized intermediate C, which
upon hemiketal formation would give betaine D. Continu-
ing from D, a carbon to oxygen shift of the phosphonium
ligand, i.e., via the unchanged intermediate E, would give
the alternative beatine F, from which the formation of 17,
via tautomerization and elimination of triphenylphosphin-
oxide (POPh3), can be easily explained.
It should be borne in mind that the original FK 506
and ascomycin skeleton have a C=O functionality at po-
sition 22, which it was necessary to reduce in the reaction
sequence to remove the cyclohexyl moiety (see Scheme
2). Finally, this position has to be restored to get back
the intact effector domain (see Scheme 1). The oxidative
restoration of the C-22 carbonyl in selected C-28 modified
compounds was accomplished with Dess-Martin perio-
dinane.18,19 Applying these oxidation conditions to pre-
cursor 5 and it derivatives Z-7, 14a and 15, we obtained
20 R. ZIMMER et al.






















































the desired oxidation products 19–22 in reasonable yields
(50–66 %, Scheme 7). According to the NMR studies,
the resulting modified ascomycin compounds 19–22 exist
in deuterochloroform solution as a mixture of two con-
formers (cis/trans-amide rotamers). Ratios of the confor-
mers were 3 : 2 (19, 22), 2 : 1 (Z-20) and 1 : 1 (21).
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5 (X = O)
Z-7 (X = NOBn)
54 % (3:2) 19 (X = O)
56 % (2:1) Z-20 (X = NOBn)
(R = TBDMS)
r. t., 2–6 h
14a (X = CH2CO2Me; H)
15 (X = Me; H)
50 % (1:1) 21 (X = CH2CO2Me; H)
66 % (3:2) 22 (X = Me; H)
Scheme 7.
EXPERIMENTAL
All reactions were performed in flame-dried reaction ves-
sels under a slight pressure of dry Ar. Solvents were dried
by standard methods. All other commercially available re-
agents were applied without further purification. All reac-
tions were monitored by TLC on glass backed silica-gel
plates with fluorescent stain (UV detection at max = 254
nm); visualization of the reaction components was effected
by spraying with a solution of molybdatophosphoric acid
(20 % in EtOH–H2O, 3 : 1). Column chromatography: sil-
ica gel (0.040–0.063 mm), from E. MERCK. 1H and
13C NMR Spectra: Bruker WM 250 and Bruker AMX 500;
the solvent CDCl3 was used as internal standard (H) =
7.27, C) = 77.0 ppm); due to complicated overlapping,
only relevant 1H NMR data are reported. Mass spectra: fast
atom bombardment (FAB) spectra; VG 70-SE instrument







NH2OH · HCl (116 mg, 1.67 mmol) was added to a solution
of 28-oxoascomycin 5 (131 mg, 0.167 mmol) in dry ethanol
(3 ml). After stirring at r.t. for 24 h, the solution was concen-
trated in vacuo. The residue was disolved in CH2Cl2 (5 ml)
and washed subsequently with H2O and brine. The organic
phase was dried (MgSO4) and the solvent was evaporated
in vacuo. The crude product was submitted to column chro-
matography (silica gel, toluene–AcOEt 6 : 1): 6 (79 mg,
59 %). Mixture of two isomers (60 : 40), major isomer:
1H NMR (CDCl3) /ppm: 8.04 (s, 1 H, NOH); 5.65 (d, J =
2.5 Hz, 1 H, 26-H); 5.38 (d, J = 2 Hz, 1 H, 2-H); 4.88 (d,
J = 10 Hz, 1 H, 20-H); 3.38, 3.28 (2 s, 3 H each, 2 MeO);
1.85 (s, 3 H, 28-Me); 1.63 (s, 3 H, 19-Me); 1.02 (d, J =
6.5 Hz, 3 H, 17-Me); 0.99 (s, 9 H, SitBu); 0.18, 0.16 (2 s,
3 H each, SiMe2). 13C NMR (CDCl3) /ppm: 198.3 (C-9);
169.1 (C-1); 166.1 (C-8); 155.5 (C-28); 136.4 (C-19); 125.4
(C-20); 99.0 (C-10); 76.5, 74.4, 74.1, 73.8, 73.7, 73.4 (C-13,
C-14, C-15, C-22, C-24, C-26); 56.9, 56.4, 56.3 (C-2, 2
MeO); 49.3 (C-18); 44.7 (C-21); 39.2, 38.8 (C-6, C-25);
35.6, 34.7 (C-11, C-23); 33.0 (C-16); 32.5 (C-12); 27.9
(C-17); 26.8 (C-36); 26.5 (C-3); 26.0 (SitBu); 24.5 (C-5);
22.0, 21.5 (C-4, 17-Me); 18.2 (Si-C); 16.1, 15.4 (19-Me,
28-Me); 12.1, 11.8 (C-37, 11-Me); 10.7 (25-Me); –3.9, –4.6







O-Benzylhydroxyl amine (625 mg, 5.08 mmol) and PPTS
(10 mg) were added to a solution of 5 (398 mg, 0.508 mmol)
in anhydrous benzene (10 ml) and the solution was stirred at
r.t for 5 d. Concentration of the solution and purification by
column chromatography (silica gel, toluene–EtOAc 6 : 1) af-
forded 7 (375 mg, 83 %) as colorless foam. Mixture of two
isomers (Z-7 : E-7 = 81 : 19). Major isomer Z-7: 1H NMR
(CDCl3) /ppm: 7.38–7.13 (m, 5 H, Ph); 6.31 (d, J = 2.5 Hz,
1 H, 26-H); 5.57 (d, J = 2 Hz, 1 H, 10-OH); 5.10, 5.06 (AB
system, JAB = 12.5 Hz, 2 H, CH2O); 4.91 (d, J = 10 Hz, 1 H,
20-H); 4.46 (d, J = 12.5 Hz, 1 H, 6-Heq); 4.25 (d, J = 6 Hz,
1 H, 2-H); 3.35, 3.28 (2 s, 3 H each, 2 MeO); 3.04 (dt, J = 3,
13.5 Hz, 1 H, 6-Hax); 2.02 (t, J = 13.5 Hz, 1 H, 3-Heq); 1.79
(s, 3 H, 28-Me); 1.60 (s, 3 H, 19-Me); 1.03 (d, J = 6.5 Hz,
3 H, 17-Me); 0.94 (s, 9 H, SitBu); 0.08, 0.01 (2 s, 3 H each,
SiMe2). 13C NMR (CDCl3) /ppm:198.8 (C-9); 169.5 (C-1);
166.2 (C-8); 156.7 (C-28); 137.8, 136.2, 128.6, 128.2, 127.8
(C-19, Ph); 125.2 (C-20); 99.3 (C-10); 76.5 (C-15); 76.0
(OCH2); 74.8 (C-24); 74.5 (C-13); 73.8 (C-14); 73.4 (C-22);
72.0 (C-26); 56.7, 56.4, 56.3 (C-2, 2 MeO); 49.2 (C-18);
44.3 (C-21); 38.6 (C-6); 36.6 (C-25); 34.8, 34.7 (C-11, C-23);
33.4 (C-16); 32.5 (C-12); 28.0 (C-17); 26.8 (C-36); 26.4
(C-3); 26.0 (SitBu); 24.0 (C-5); 22.1, 22.0 (C-4, 17-Me);
18.3 (Si-C); 17.3 (28-Me); 16.2 (19-Me); 12.0 (C-37); 11.8
(25-Me); -4.6, -4.9 (SiMe2). Minor isomer E-7: 1H NMR
(CDCl3) /ppm: 7.38–7.13 (m, 5 H, Ph); 5.62 (d, J = 2.5 Hz,
1 H, 10-OH); 5.32 (d, J = 2 Hz, 1 H, 26-H); 4.32 (d, J =
10 Hz,1 H, 20-H); 4.32 (d, J = 12.5 Hz, 1 H, 6-Heq); 3.34,
3.25 (2 s, 3 H each, 2 MeO); 1.83 (s, 3 H, 28-Me); 0.98 (s,
9 H, SitBu); 0.16, 0.13 (2 s, 3 H each, SiMe2). 13C NMR
(CDCl3) /ppm: 198.4 (C-9); 168.9 (C-1); 166.0 (C-8); 154.1
(C-28); 138.2, 136.2, 128.0, 127.7, 127.0 (C-19, Ph); 125.4
(C-20); 98.9 (C-10); 49.0 (C-18); 44.7 (C-21); 38.8 (C-6);








According to the preparation of 7, a mixture of 5 (210 mg,
0.268 mmol), O-(2-hydroxyethyl)-hydroxylamine (8) (413 mg,
5.36 mmol) and PPTS (20 mg) in benzene–ethanol (5 : 1,
12 ml) was stirred for 6 days at r.t. Purification by column
chromatography (hexane–EtOAc 1 : 1) afforded the 28-oxime
ether 9 (198 mg, 88 %) as colorless foam. Mixture of two
isomers (Z-9 : E-9 = 75 : 25). Major isomer Z-9: 1H NMR
(CDCl3) /ppm: 6.31 (d, J = 3.5 Hz, 1 H, 26-H); 5.57 (d,
J = 2 Hz, 1 H, 10-OH); 4.92 (d, J = 10 Hz, 1 H, 20-H); 4.46
(d, J = 13 Hz, 1 H, 6-Heq); 4.28 (d, J = 7 Hz, 1 H, 2-H);
4.16 (t, J = 4.5 Hz, 2 H, OCH2); 3.95-3.78 (m, 4 H, 22-H,
24-H, CH2OH); 3.37, 3.29 (2 s, 3 H each, 2 MeO); 3.08 (d,
J = 1.8 Hz, 1 H, 22-OH); 3.02 (dt, J = 3, 13 Hz, 1 H, 6-Hax);
1.82 (s, 3 H, 28-Me); 1.62 (s, 3 H, 19-Me); 1.04 (d, J = 6.5
Hz, 3 H, 17-Me); 1.02 (s, 9 H, SitBu); 0.95 (d, J = 7 Hz,
3 H, 25-Me); 0.86 (t, J = 7.5 Hz, 3 H, 37-H); 0.84 (d, J =
6.5 Hz, 3 H, 11-Me); 0.20, 0.19 (2 s, 3 H each, SiMe2).
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13C NMR (CDCl3) /ppm: 198.7 (C-9); 169.9 (C-1); 166.2
(C-8); 157.6 (C-28); 136.3 (C-19); 125.2 (C-20); 99.3 (C-10);
76.7 (C-15); 74.7 (C-24, OCH2); 74.3 (C-13); 73.8 (C-14);
73.3 (C-22); 71.7 (C-26); 62.5 (CH2OH); 56.7 (C-2); 56.4,
56.3 (2 MeO); 49.2 (C-18); 44.4 (C-21); 38.7 (C-6); 37.1
(C-25); 34.8, 34.7 (C-11, C-23); 33.4 (C-16); 32.4 (C-12);
28.0 (C-17); 26.8 (C-36); 26.4 (C-3); 26.0 (SitBu); 24.0 (C-5);
22.0 (17-Me); 21.9 (C-4); 18.3 (Si-C); 17.2 (28-Me); 16.1
(19-Me); 15.2 (11-Me); 12.0 (C-37); 11.9 (25-Me); –4.5,
–4.8 (SiMe2). FAB-MS: m/z: 803 (M + Li+), 709, 691,
673, 286, 266. Minor isomer E-9: 1H NMR (CDCl3) /ppm:
5.64 (d, J = 3 Hz, 1 H, 26-H); 5.35 (d, J = 1.5 Hz, 1 H,
10-OH); 4.78 (d, J = 10 Hz, 1 H, 20-H); 4.27 (d, J = 10 Hz,
1 H, 6-Heq); 4.19 (d, J = 3 Hz, 1 H, 2-H); 3.36, 3.28 (2 s, 3
H each, 2 MeO); 2.82 (d, J = 2 Hz, 1 H, 22-OH); 1.83 (s, 3
H, 28-Me); 1.61 (s, 3 H, 19-Me); 1.03 (d, J = 6.5 Hz, 3 H,
17-Me); 1.00 (s, 9 H, SitBu); 0.89 (d, J = 6 Hz, 3 H, 25-Me);
0.86 (d, J = 6 Hz, 3 H, 11-Me); 0.85 (t, J = 7 Hz, 3 H, 37-H);
0.19, 0.16 (2 s, 3 H each, SiMe2). 13C NMR (CDCl3) /ppm:
198.4 (C-9); 169.2 (C-1); 166.1 (C-8); 155.3 (C-28); 136.5
(C-19); 125.3 (C-20); 99.0 (C-10); 76.5 (C-15); 74.7 (C-24);
74.4 (C-13); 74.0, 73.8, 73.7 (C-14, (C-26, OCH2); 73.4
(C-22); 63.1 (CH2OH); 55.8 (C-2); 56.4, 56.3 (2 MeO); 49.2
(C-18); 44.8 (C-21); 39.0, 38.8 (C-6, C-25); 35.4 (C-11);
34.7 (C-23); 33.0 (C-16); 32.5 (C-12); 27.9 (C-17); 26.8
(C-36); 26.5 (C-3); 25.9 (SitBu); 24.1 (C-5); 21.9 (17-Me);
21.5 (C-4); 18.2 (Si-C); 16.0 (19-Me); 15.4 (11-Me); 12.4







A solution of 5 (150 mg, 0.191 mmol), semicarbazide hydro-
chloride (107 mg, 0.958 mmol) and NaOAc (110 mg, 1.34
mmol) in ethanol–H2O (5 : 1, 12 ml) was stirred at 70 °C
for 48 h. After removal of the solvents, the residue was dis-
solved in EtOAc (10 ml) and the resulting solution was
washed with H2O. The organic phase was dried (MgSO4)
and evaporated in vacuo. Column chromatography (CH2Cl2–
methanol 97 : 3) of the residue yielded 10 (82.5 mg, 51 %).
Mixture of two isomers (94 : 6). Major isomer 10: 1H NMR
(CDCl3) /ppm: 5.64 (d, J = 2.5 Hz, 1 H, NH); 5.43 (d, J =
1.5 Hz, 1 H, 26-H); 4.89 (d, J = 10 Hz, 1 H, 20-H); 4.41 (d,
J = 10 Hz, 1 H, 6-Heq); 4.29 (d, J = 4 Hz, 1 H, 2-H); 3.36,
3.29 (2 s, 3 H each, 2 MeO); 1.94 (s, 3 H, 28-Me); 1.61 (s,
3 H, 19-Me); 0.97 (s, 9 H, SitBu); 0.20, 0.17 (2 s, 3 H each,
SiMe2). 13C NMR (CDCl3) /ppm: 198.3 (C-9); 169.3 (C-1);
166.0 (C-8); 157.9 (C-28); 147.4 (CONH2); 136.4 (C-19);
125.3 (C-20); 99.0 (C-10); 76.4, 75.1, 74.2, 74.0, 73.7, 73.4
(C-13, C-14, C-15, C-22, C-24, C-26); 56.7, 56.3, 56.2 (C-2,
2 MeO); 49.2 (C-18); 44.7 (C-21); 39.9 (C-6); 38.7 (C-25);
35.3, 34.6 (C-11, C-23); 33.0 (C-16); 32.0 (C-12); 27.8
(C-17); 26.8 (C-36); 26.4 (C-3); 25.9 (SitBu); 24.0 (C-5);
21.9, 21.5 (C-4), 17-Me); 18.1 (Si-C); 16.0, 15.3, 13.4
(11-Me, 19-Me, 28-Me); 12.0 (C-37); 10.8 (25-Me); –4.0,
–4.7 (SiMe2). FAB-MS: m/z: 839 (M+), 707, 689, 671, 522,








p-Toluenesulfonic acid hydrazide (36.5 mg, 0.196 mmol)
was added to a solution of 5 (77 mg, 0.098 mmol) in AcOH
(1 ml) and the mixture was stirred at r.t. for 25 h. The reac-
tion mixture was poured into a sat. aq. NaHCO3 solution (2
ml) and extracted with EtOAc. The combined organic lay-
ers were washed with brine and dried (MgSO4). Removal
of the solvent in vacuo and purification by column chroma-
tography (hexane–EtOAc 2 : 1) afforded 11 (49 mg, 53 %)
as colorless foam. One isomer. 1H NMR (CDCl3) /ppm:
7.89 (br. s, 1 H, NH); 7.81–7.70, 7.30–7.25 (2 m, 2 H each,
C6H4); 5.55 (d, J = 2.5 Hz, 1 H, 26-H); 4.86 (d, J = 10 Hz,
1 H, 20-H); 4.33 (d, J = 13.5 Hz, 1 H, 6-Heq); 3.36, 3.29 (2
s, 3 H each, 2 MeO); 2.43 (s, 3 H, C6H4Me); 1.73 (s, 3 H,
28-Me); 1.60 (s, 3 H, 19-Me); 0.97 (s, 9 H, SitBu); 0.63 (d,
J = 7 Hz, 3 H, 25-Me); 0.15, 0.12 (2 s, 3 H each, SiMe2).
13C NMR (CDCl3) /ppm: 198.5 (C-9); 169.4 (C-1); 166.1
(C-8); 154.4 (C-28); 144.0, 136.5, 135.5, 129.5, 127.9 (C-19,
C6H4); 125.3 (C-20); 99.0 (C-10); 76.4, 75.0 (C-15, C-26);
74.3 (C-13); 73.9, 73.8, 73.3 (C-14, C-22, C-24); 56.8, 56.4,
56.3 (C-2, 2 MeO); 49.3 (C-18); 44.7 (C-21); 39.6, 38.7 (C-6,
C-25); 35.3, 35.0 (C-11, C-23); 33.2 (C-16); 32.4 (C-12);
27.9 (C-17); 26.8, 26.4 (C-3, C-36); 25.9 (SitBu); 24.1 (C-5);
22.0, 21.6, 21.3 (C-4, 17-Me, 28-Me); 18.1 (Si-C); 16.1
(19-Me); 15.4 (11-Me); 13.5 (C6H4Me); 12.1 (C-37); 10.3







A solution of 5 (125 mg, 0.160 mmol) and trimethylsilyl
cyanide (158 mg, 1.60 mmol) in CH2Cl2 (6 ml) was treated
with BF3 · OEt2 (10 drops) for 3.5 h at –10 °C. Work up
with sat. aq. NaHCO3 solution, extraction with CH2Cl2, dry-
ing with MgSO4 and evaporation of the solvent afforded the
crude product. Column chromatography (hexane–EtOAc 3 : 1)
of the crude product gave the cyano-substituted derivative
12 (49 mg, 36 %) as colorless foam. Mixture of two dia-
stereomers (60 : 40). Major isomer 12: 1H NMR (CDCl3)
/ppm: 5.40 (d, J = 2 Hz, 1 H, 26-H); 5.13 (s, 1 H, 10-OH);
4.40 (d, J = 10 Hz, 1 H, 20-H); 3.37, 3.29 (2 s, 3 H each, 2
MeO); 1.60 (s, 3 H, 19-Me); 1.26 (s, 3 H, 28-Me); 1.16 (d,
J = 7 Hz, 3 H, 17-Me); 0.97 (s, 9 H, SitBu); 0.19, 0.16 (2 s,
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3 H each, SiMe2). 13C NMR (CDCl3) /ppm: 198.6 (C-9);
173.1 (C-1); 166.1 (C-8); 137.0 (C-19); 125.0 (C-20); 119.8
(28-CN); 98.9 (C-10); 79.3, 77.1, 75.3, 74.2, 74.1, 73.7, 73.2
(C-13, C-14, C-15, C-22, C-24, C-26, C-28); 57.6, 56.4, 56.3
(C-2, 2 MeO); 49.3 (C-18); 45.0 (C-21); 38.3, 37.7, 36.0,
34.7, 32.9, 32.6 (C-6, C-11, C-12, C-16, C-23, C-25); 27.6,
26.7 (C-3, C-36); 25.0, 24.2 (C-4, C-5); 25.9 (SitBu); 21.7
(28-Me); 18.2 (Si-C); 16.0 (19-Me); 15.5 (11-Me); 12.1
(C-37); 10.7 (25-Me); –4.0, –4.5 (SiMe2). FAB-MS: m/z:








According to the preparation of 12, a mixture of 5 (110
mg, 0.140 mmol), O-silyl ketene acetal 13 (0.5 ml) and
BF3 · OEt2 (10 drops) in CH2Cl2 (5 ml) was stirred for 4 h at
–40 °C and then worked up. Purification by column chroma-
tography (hexane–EtOAc 4 : 1) of the crude product gave 14
(57 mg, 48 %) as colorless foam. Mixture of two diastereomers
(70 : 30). Major diastereomer 14: 1H NMR (CDCl3) /ppm:
5.40 (d, J = 2 Hz, 1 H, 26-H); 4.90 (d, J = 1.5 Hz, 1 H,
10-OH); 4.82 (d, J = 10 Hz, 1 H, 20-H); 4.46 (d, J = 14 Hz,
1 H, 6-Heq); 4.36 (t, J = 3 Hz, 1 H, 2-H); 3.72 (s, 3 H,
CO2Me); 3.36, 3.28 (2 s, 3 H each, 2 MeO); 3.30 (s, 1 H,
OH); 2.52, 2.44 (AB system, JAB = 15 Hz, 2 H, 28-CH2);
1.63 (s, 3 H, 19-Me); 1.32 (s, 3 H, 28-Me); 1.01 (d, J = 7
Hz, 3 H, 17-Me); 0.98 (s, 9 H, SitBu); 0.80 (t, J = 7 Hz, 3 H,
37-H); 0.16, 0.10 (2 s, 3 H each, SiMe2). 13C NMR (CDCl3)
/ppm: 198.2 (C-9); 172.2, 169.6 (C-1, CO2Me); 165.9
(C-8); 136.7 (C-19); 125.8 (C-20); 98.6 (C-10); 76.2, 76.0,
75.1, 74.1, 74.0, 73.7, 73.5 (C-13, C-14, C-15, C-22, C-24,
C-26, C-28); 57.9, 56.4, 56.3 (C-2, 2 MeO); 51.8 (CO2Me);
49.4 (C-18); 45.3, 43.6 (C-21, 28-CH2); 39.1, 38.5 (C-6,
C-25); 36.3, 34.8 (C-11, C-23); 32.6, 32.5 (C-12, C-16);
27.5 (C-17); 26.7, 26.6 (C-3, C-36); 26.1 (SitBu); 24.9,
24.0 (C-5, 28-Me); 22.1, 21.7 (C-4, 17-Me); 18.1 (Si-C);
15.9, 15.6 (11-Me, 19-Me); 12.6, 12.0 (C-37, 25-Me); –3.8,
–4.4 (SiMe2). FAB-MS: m/z: 856 (M+), 838 (M+ – H2O), 820
(M+- 2 H2O), 706, 688, 281, 221, 183. Minor diastereomer
14: 1H NMR (CDCl3) /ppm: 5.43 (d, J = 2 Hz, 1 H, 26-H);
4.82 (d, J = 9.5 Hz, 1 H, 20-H); 4.81 (d, J = 2 Hz, 1 H,
10-OH); 4.48 (d, J = 14 Hz, 1 H, 6-Heq); 4.41 (br. s, 1 H,
2-H); 4.19 (s, 1 H, OH); 3.74 (s, 3 H, CO2Me); 3.38, 3.23
(2 s, 3 H each, 2 MeO); 2.58, 2.40 (AB system, JAB = 16 Hz,
2 H, 28-CH2); 1.60 (s, 3 H, 19-Me); 1.26 (s, 3 H, 28-Me);
0.98 (s, 9 H, SitBu); 0.82 (t, J = 7 Hz, 3 H, 37-H); 0.16,
0.08 (2 s, 3 H each, SiMe2). 13C NMR (CDCl3) /ppm: 197.9
(C-9); 173.0, 169.2 (C-1, CO2Me); 165.8 (C-8); 136.4 (C-19);
126.2 (C-20); 98.3 (C-10); 75.9, 75.6, 75.1, 74.0, 73.9, 73.3,
73.1 (C-13, C-14, C-15, C-22, C-24, C-26, C-28); 51.9
(CO2Me); 49.3 (C-18); 45.2, 43.0 (C-21, 28-CH2); 39.1,
37.9 (C-6, C-25); 36.2, 34.8 (C-11, C-23); 32.6, 32.4 (C-12,
C-16); 27.3 (C-17); 26.7, 26.6 (C-3, C-36); 26.1 (SitBu); 24.4,
24.2 (C-5, 28-Me); 22.3, 21.5 (C-4, 17-Me); 18.1 (Si-C);








MeLi (0.48 ml, 0.768 mmol; 1.6 M solution in hexane) was
added dropwise to a solution of 5 (150 mg, 0.192 mmol) in
anhydrous THF (10 ml) at –60 °C. After stirring at –60 °C
for 3.5 h, the mixture was quenched with sat. aq. NH4Cl so-
lution followed by extraction with tert-butyl methyl ether.
The combined organic phases were dried (MgSO4) and
concentrated in vacuo. The residue was purified by column
chromatography (hexane–EtOAc 5 : 1): 15 (30 mg, 20 %)
and the starting material 4 (41 mg, 27 %). Compound 15:
1H NMR (CDCl3) /ppm: 5.33 (d, J = 2 Hz, 1 H, 26-H);
4.90 (d, J = 1.5 Hz, 1 H, 10-OH); 4.82 (d, J = 10 Hz, 1 H,
20-H); 4.45 (d, J = 13.5 Hz, 1 H, 6-Heq); 3.35, 3.27 (2 s, 3 H
each, 2 MeO); 1.59 (s, 19-Me); 1.24, 1.20 (2 s, 3 H each,
28-Me); 1.00 (d, J = 7 Hz, 3 H, 17-Me); 0.97 (s, 9 H, SitBu);
0.15, 0.11 (2 s, 3 H each, SiMe2). 13C NMR (CDCl3) /ppm:
198.1 (C-9); 170.1 (C-1); 165.9 (C-8); 136.7 (C-19); 125.8
(C-20); 98.5 (C-10); 78.6 (C-26); 76.0, 75.1, 73.9, 73.7, 73.4,
73.2 (C-13, C-14, C-15, C-22, C-24, C-28); 57.8, 56.4, 56.3
(C-2, 2 MeO); 49.3 (C-18); 45.1 (C-21); 39.0, 38.7 (C-6,
C-25); 36.1, 34.7, 34.5, 32.5 (C-11, C-12, C-16, C-23); 28.5
(C-17); 27.4, 26.7 (C-3, C-36); 26.0 (SitBu); 25.3, 24.3
(C-5, 28-Me); 21.9, 21.6 (C-4, 17-Me); 18.1 (Si-C); 15.9,
15.6 (11-Me, 19-Me); 12.2, 11.9 (C-37, 25-Me); –3.8, –4.4
(SiMe2). FAB-MS: m/z: 799 (M+), 648, 630, 187, 130, 123,
111.
Reaction of 24-O-tert-butyldimethylsilyl-22(R)-dihydro-
28-oxoascomycin (5) with Wittig reagent 16
The Wittig reagent 16 (777 mg, 2.44 mmol) was added to a
solution of 5 (191 mg, 0.244 mmol) in dry MeCN (10 ml)
and the mixture was stirred at 65 °C for 10 d. Then the sus-
pension was filtered and the resulting filtrate was concentrat-
ed in vacuo. Column chromatography (cyclohexane–EtOAc
2 : 1) of the residue yielded 17 (22 mg, 11 %) and 18 (8
mg, 4 %). Compound 17: 1H NMR (CDCl3) /ppm: 5.63
(d, J = 5 Hz, 1 H, 2-H); 5.22 (d, J = 5.5 Hz, 1 H, 26-H);
4.75 (d, J = 10.5 Hz, 1 H, 20-H); 3.90 (d, J = 12.5 Hz, 1 H,
6-Heq); 3.78 (q, J = 5.5 Hz, 1 H, 24-H); 3.26 (dd, J = 4, 11
Hz, 1 H, 15-H); 3.22 (s, 3 H, 15-OMe); 3.10 (dd, J = 9.5,
14 Hz, 1 H, 14-H); 2.78 (s, 3 H, 13-OMe); 2.70 (dd, J = 8,
9 Hz, 1 H, 13-H); 2.63 (br s, 1 H, 22-OH); 2.59 (d, J = 1 Hz,
1 H, 24-OH); 2.28 (s, 3 H, 28-Me); 2.18 (s, 3 H, MeCH=);
2.17 (s, 3 H, MeC=O); 1.64 (s, 3 H, 19-Me); 1.32 (d, J = 7
Hz, 3 H, 11-Me); 0.95 (d, J = 7 Hz, 3 H, 25-Me); 0.91 (s, 9
H, SitBu); 0.83 (d, J = 6.5 Hz, 3 H, 17-Me); 0.12, 0.09 (2 s,
3 H each, SiMe2). 13C NMR (CDCl3) /ppm: 205.7 (C=O);
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203.9 (C-28); 172.8 (C-1); 166.0 (C-8); 154.0 (C-10); 147.9
(=C–O); 136.6 (C-19); 126.6 (C-20); 117.6 (C-9); 112.1
(=C–CH2); 79.4 (C-26); 77.9 (C-13); 77.3 (C-15); 74.3 (C-14);
74.1 (C-24); 73.6 (C-22); 58.1 (15-OMe); 55.6 (13-OMe);
50.9 (C-2); 49.9 (C-18); 47.5 (C-21); 45.3 (C-6); 40.4 (C-25);
38.9 (C-12); 38.5 (CH2C=O); 36.5 (C-23); 34.2 (C-16); 32.0
(C-11); 29.5 (MeC=O); 28.1 (28-Me); 26.4 (C-3); 26.4
(C-17); 25.9 (SitBu); 25.7 (C-5); 25.2 (C-36); 21.0 (C-4);
20.0 (17-Me); 18.5 (11-Me); 17.9 (Si–C); 15.9 (19-Me); 12.7
(25-Me); 11.4 (C-37, =CMe); –4.3, –4.7 (SiMe2). FAB-MS:
m/z: 868 (M + Li+), 249, 227. Compound 18: 1H NMR
(CDCl3) /ppm: 6.00 (s, 1 H, =CH); 5.92 (d, J = 2 Hz, 1 H,
26-H); 5.04 (d, J = 4.5 Hz, 1 H, 2-H); 4.81 (d, J = 10 Hz, 1 H,
20-H); 4.46 (d, J = 11 Hz, 1 H, 6-Heq); 3.89 (dd, J = 5.5,
12 Hz, 1 H, 24-H); 3.67 (br dd, J = 3.5, 9 Hz, 1 H, 22-H);
3.36, 3.29 (2 s, 3 H each, 2 MeO); 2.98 (dt, J = 3.5, 13.5
Hz, 1 H, 6-Hax); 2.13 (s, 3 H, 28-Me); 1.69 (s, 3 H, 19-Me);
1.49 (s, 3 H, MeC–O); 1.04 (d, J = 6.5 Hz, 3 H, 17-Me);
0.95 (s, 9 H, SitBu); 0.93 (d, J = 6.5 Hz, 3 H, 11-Me); 0.89
(d, J = 7 Hz, 3 H, 25-Me); 0.85 (t, J = 7 Hz, 3 H, 37-H);
0.70 (dd, J = 13.3, 13.5 Hz, 1 H, 16-H); 0.15, 0.13 (2 s, 3 H
each, SiMe2). 13C NMR (CDCl3) /ppm: 207.1 (C-28); 171.8
(C-1); 166.2 (C-8); 138.6 (C-9, C-19); 131.2 (=CH); 125.4
(C-20); 111.6 (C-10); 110.6 (C–O); 77.3 (C-26); 76.5 (C-15);
76.2 (C-14); 74.5 (C-13); 73.0 (C-22); 72.1 (C-24); 58.4
(C-2); 56.4, 56.3 (2 OMe); 49.6 (C-18); 47.3 (C-21); 40.1
(C-25); 39.1 (C-6); 35.8 (C-23); 34.5 (C-11); 33.4 (C-12);
32.5 (C-16); 28.9 (C-17); 27.3 (28-Me); 26.1 (C-3, C-36);
25.9 (SitBu); 24.3 (C-5); 21.7, 21.6 (C-4, 17-Me); 21.1
(MeC–O); 18.1 (Si–C); 17.1 (19-Me); 16.3 (11-Me); 13.3
(C-37); 11.0 (25-Me); –3.7, –4.3 (SiMe2). FAB-MS: m/z: 810
(M + Li+), 672, 654, 227.
Oxidation of the C-22 Hydroxy Group by Dess Martin
Periodinane; General Procedure. – The appropriate 22(R)-
dihydroascomycin derivative (1 equiv.) and pyridine (6–12
equiv.) were dissolved in CH2Cl2 (50 ml/1 mmol of substra-
te). After addition of Dess Martin periodinane (3–4 equiv.),
the suspension was stirred at r.t. for the time indicated. The
reaction was quenched with 10 % Na2SO3 solution and the
resulting mixture was extracted with CH2Cl2. The combin-
ed organic phases were dried (MgSO4) and concentrated in
vacuo. The resulting crude product was purified by column






According to the general procedure, compound 5 (0.113 g,
0.144 mmol), Dess Martin periodinane (0.188 g, 0.433 mmol)
and pyridine (0.063 g, 0.796 mmol) afforded 19 (0.061 g,
54 %). Reaction time: 2 h. Mixture of two conformers
(60 : 40). Major conformer: 1H NMR (CDCl3) /ppm: 5.44
(d, J = 2.5 Hz, 1 H, 26-H); 4.78 (d, J = 10 Hz, 1 H, 20-H);
4.10 (d, J = 1 Hz, 1 H, 10-OH); 3.71 (dd, J = 1, 10 Hz, 1 H,
14-H); 3.38, 3.28 (2 s, 3 H each, 2 MeO); 2.80 (dt, J = 3,
13.5 Hz, 1 H, 6-Hax); 2.19 (s, 3 H, 28-Me); 1.60 (s, 3 H,
19-Me); 1.03 (d, J = 6.5 Hz, 3 H, 17-Me); 0.91 (s, 9 H,
SitBu); 0.12, 0.05 (2 s, 3 H each, SiMe2). 13C NMR (CDCl3)
/ppm: 211.0 (C-22); 203.0 (C-28); 196.4 (C-9); 169.7 (C-1);
164.6 (C-8); 138.8 (C-19); 123.5 (C-20); 97.5 (C-10); 77.2
(C-26); 74.9, 73.7, 72.8, 71.1 (C-13, C-14, C-15, C-24); 57.1,
56.3, 55.5 (C-2, 2 MeO); 48.6 (C-18); 44.3 (C-21); 39.4, 39.1
(C-6, C-25); 34.7, 33.0, 32.7, 32.2 (C-11, C-12, C-16, C-23);
27.1, 26.5, 26.1, 25.4 (C-3, C-17, C-36, 28-Me); 25.8 (SitBu);
24.0 (C-5); 20.4, 19.9 (C-4, 17-Me); 18.1 (Si-C); 16.2 (19-Me);
15.1 (11-Me); 11.4 (C-37); 10.1 (25-Me); –4.1, –4.9 (SiMe2).







According to the general procedure, compound (Z)-7 (0.088 g,
0.099 mmol), Dess Martin periodinane (0.168 g, 0.396
mmol) and pyridine (0.068 g, 0.860 mmol) afforded (Z)-20
(0.049 g, 56 %). Reaction time: 4 h. Mixture of two con-
formers (67 : 33). Major conformer (Z)-20: 1H NMR (CDCl3)
/ppm: 7.35–7.25 (m, 5 H, Ph); 6.14 (d, J = 3.5 Hz, 1 H,
26-H); 5.80 (s, 1 H, 10-OH); 5.08, 5.04 (AB system, JAB =
13 Hz, 2 H, CH2O); 4.79 (d, J = 10 Hz, 1 H, 20-H); 3.95
(dd, J = 2.5, 9.5 Hz, 1 H, 14-H); 3.35, 3.27 (2 s, 3 H each, 2
MeO); 1.78 (s, 3 H, 28-Me); 1.66 (s, 3 H, 19-Me); 1.05 (d,
J = 6.5 Hz, 3 H, 17-Me); 0.82 (s, 9 H, SitBu); –0.01, –0.05
(2 s, 3 H each, SiMe2). 13C NMR (CDCl3) /ppm: 210.9
(C-22); 192.0 (C-9); 168.9 (C-1); 166.1 (C-8); 155.9 (C-28);
139.3, 128.3, 128.1, 127.9, 127.6 (C-19, Ph); 123.3 (C-20);
98.8 (C-10); 76.4, 76.0, 75.8, 75.5, 74.8, 74.6, 70.3 (C-13,
C-14, C-15, C-22, C-24, C-26, OCH2); 57.5, 56.3, 55.3 (C-2,
2 MeO); 52.2, 48.7, 43.6 (C-18, C-21, C-23); 39.7, 36.3 (C-6,
C-25); 33.3, 32.7, 32.4 (C-11, C-12, C-17); 26.8 (C-36); 26.4
(C-3); 25.8 (SitBu); 24.4, 23.3, 21.0 (C-4, C-5, 17-Me);
18.8 (Si-C); 17.2 (28-Me); 16.2 (19-Me); 15.7 (11-Me);
12.0 (C-37); 11.6 (25-Me); –4.7, –4.9 (SiMe2). FAB-MS:







According to the general procedure, compound 14a (0.133 g,
0.155 mmol), Dess Martin periodinane (0.263 g, 0.620 mmol)
and pyridine (0.147 g, 1.86 mmol) afforded 21 (0.066 g, 50 %).
Reaction time: 6 h. Mixture of two conformers (50 : 50), both
conformers of 21: 1H NMR (CDCl3) /ppm: 5.26 (d, J = 3 Hz,
1 H, 26-H); 4.84, 4.77 (2 d, J = 10 Hz each, 1 H, 20-H);
3.70, 3.67 (2 s, 3 H, 2 CO2Me); 3.37, 3.36, 3.33, 3.25 (4 s,
3 H each, 4 MeO); 1.74, 1.57 (2 s, 3 H, 19-Me); 1.26, 1.23
(2 s, 3 H, 28-Me); 0.99, 0.91 (2 d, J = 6.5 Hz each, 3 H,
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17-Me); 0.87, 0.85 (2 s, 9 H, 2 SitBu); 0.10, 0.06, 0.05,
0.04 (4 s, 6 H, 2 SiMe2). 13C NMR (CDCl3) /ppm: 210.6,
209.0 (C-22); 195.9, 194.7 (C-9); 172.3, 171.6, 169.7, 169.6,
166.0, 164.8 (C-1, C-8, CO2Me); 139.7, 137.7 (C-19); 124.0,
123.5 (C-20); 98.2, 96.9 (C-10); 78.9, 77.3, 76.6, 74.9, 73.7,
73.5, 73.4, 73.0, 72.6, 72.4, 71.7, 69.8 (C-13, C-14, C-15,
C-22, C-24, C-26, C-28); 57.2, 57.0, 56.8, 56.3, 55.1, 54.0
(C-2, 4 MeO); 52.3, 51.8 (2 CO2Me); 48.7, 48.2 (C-18);
46.0, 44.4, 43.9, 42.2 (C-21, 28-CH2); 39.8, 39.3, 35.2, 34.7,
33.0, 32.8, 32.5, 32.4, 27.3, 26.3 (C-3, C-6, C-11, C-12, C-16,
C-17, C-23, C-25, C-36); 25.9, 25.7 (2 SitBu); 24.7, 24.0,
23.1, 22.9, 21.2, 20.8, 20.2, 19.5 (C-4, C-5, 17-Me, 28-Me);
17.9 (Si-C); 16.2, 16.1, 15.9, 15.3 (11-Me, 19-Me); 13.6, 12.1
(C-37); 11.6, 11.5 (25-Me); –3.9, –4.3, –4.7, –4.8 (2 SiMe2).
FAB-MS of the desilylated compound of 21 (HF/MeCN; r.t.,








According to the general procedure, compound 15 (0.032 g,
0.040 mmol), Dess Martin periodinane (0.068 g, 0.160 mmol)
and pyridine (0.038 g, 0.480 mmol) afforded 22 (0.021 g,
66 %). Reaction time: 4 h. Mixture of two conformers
(60 : 40). Major conformer 22: 1H NMR (CDCl3) /ppm:
5.22 (d, J = 2.5 Hz, 1 H, 26-H); 4.74 (d, J = 10 Hz, 1 H,
20-H); 3.37, 3.27 (2 s, 3 H each, 2 MeO); 1.61 (s, 3 H, 19-Me);
1.24 (s, 3 H, 28-Me); 0.89 (s, 9 H, SitBu); 0.14, 0.09 (2 s, 3
H each, SiMe2). 13C NMR (CDCl3) /ppm: 208.4 (C-22);
194.9 (C-9); 170.0 (C-1); 166.3 (C-8); 139.6 (C-19); 124.2
(C-20); 98.3 (C-10); 81.1, 73.7, 73.5, 72.7, 72.6, 71.6, 70.3
(C-13, C-14, C-15, C-24, C-26, C-28); 57.2, 56.9, 56.3 (C-2,
2 MeO); 48.3 (C-18); 45.2 (C-21); 40.3, 39.5, 36.2, 35.3,
32.8, 32.5 (C-6, C-11, C-12, C-16, C-23, C-25); 27.3, 26.7,
25.6 (C-3, C-17, C-36); 26.0 (SitBu); 25.1, 24.7, 22.9, 19.3
(C-4, C-5, 17-Me, 28-Me); 17.9 (Si-C); 16.0, 15.9 (11-Me,
19-Me); 14.3 (C-37); 11.6 (25-Me); –4.6, –5.1 (SiMe2).
FAB-MS of the desilylated compound of 22 (HF/MeCN;
r.t., 1.5 h): m/z: 741 (MH+), 722 (M+ – H2O), 704 (M+ – 2
H2O), 686, 266, 183, 169.
CONCLUSION
In summary, we have developed methodologies that al-
low replacement of the cyclohexylvinylidene moiety of
ascomycin (1) by various nitrogen and carbon substitu-
ents. Access to these novel macrolides with a modified
subunit is particularly important for the establishment of
structure-activity relationships.
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SA@ETAK
Preparativne modifikacije askomicina. V. Dobivanje novih derivata askomicina
pomo}u zamjene cikloheksilvinilidenske podjedinice
Reinhold Zimmer, Karl Baumann, Hildegard Sperner, Gerhard Schulz, Ewald Haidl
i Maximilian A. Grassberger
Opisani su postupci koji po~inju s lako pristupa~nim 25-O-tert-butildimetilsilil-22(R)-dihidro-28-oksoasko-
micinom i omogu}uju zamjenu askomicinske cikloheksilvinilidenske podjedinice razli~itim substituentima.
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